Guangyao Zhou

Guangyao Zhou

Auto-generated profile, based on publicly available information

Guangyao Zhou

Department of Lung Cancer, Tianjin Lung Cancer Center, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer Tianjin Medical University Cancer Institute and Hospital Tianjin China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2025 in Cell Proliferation
Verified
Journal Article
Open access
GZGuangyao Zhou
Guangyao Zhou
JTJiaxiong Tan
Jiaxiong Tan
PZPengpeng Zhang
Pengpeng Zhang
ZZZhaokai Zhou
Zhaokai Zhou
LZLianmin Zhang
Lianmin Zhang
ZZZhenfa Zhang
Zhenfa Zhang
Non‐small cell lung cancer (NSCLC) remains a leading cause of cancer mortality. Despite advancements in gene targeted therapies and immunotherapies, high heterogeneity contributes to limited efficacy and therapeutic resistance. Ubiquitination, a crucial post‐translational modification that regulates protein stability and degradation, plays a significant role in cancer pathogenesis by influencing key oncogenic pathways and tumour progression. This review systematically explores the ubiquitin‐proteasome system (UPS) and its potential as a therapeutic target for NSCLC. We highlight recent preclinical and clinical studies focusing on ubiquitination‐related biomarkers, drug targets and emerging therapies like proteasome inhibitors and Proteolysis‐targeting chimeras (PROTACs). By exploring the impact of the UPS on tumour biology, the progression of NSCLC and its response to therapy, we aim to underscore the potential of targeting the ubiquitination‐deubiquitination system as a complementary or synergistic approach to existing therapeutic strategies in NSCLC, thereby enhancing patient outcomes and overcoming treatment resistance.

6 August 2025 in Thoracic Cancer
Verified
Journal Article
Open access
YWYuan Wang
Yuan Wang
WSWei Su
Wei Su
GZGuangyao Zhou
Guangyao Zhou
YWYijie Wang
Yijie Wang
CWChunnuan Wu
Chunnuan Wu
LZLianmin Zhang
Lianmin Zhang
Introduction: Lung adenocarcinoma, the most common subtype of non‐small cell lung cancer, faces challenges such as drug resistance and tumor heterogeneity. N4‐acetylcytidine (ac4C) is an important RNA modification involved in cancer progression, but its role in lung adenocarcinoma remains unclear.Methods: This study analyzed transcriptomic and single‐cell RNA sequencing data from public databases to investigate the expression and clinical significance of ac4C‐related genes in lung adenocarcinoma. Ten machine learning algorithms were applied to develop and validate an ac4C‐related gene signature (ARGSig) for prognosis prediction across multiple independent cohorts.Results: Cells with high ac4C activity showed increased intercellular communication and activation of tumor‐associated pathways. The ARGSig model effectively stratified patients by survival outcomes and predicted sensitivity to immune checkpoint inhibitors and chemotherapy agents.Conclusion: ac4C modification and its related genes play a critical role in lung adenocarcinoma development. The ARGSig model provides a promising molecular tool for prognosis evaluation and personalized treatment guidance in lung adenocarcinoma patients.

28 May 2026 in Thoracic Cancer
Verified
Journal Article
Open access
YWYijie Wang
Yijie Wang
GZGuangyao Zhou
Guangyao Zhou
PZPengpeng Zhang
Pengpeng Zhang
ZZZhenfa Zhang
Zhenfa Zhang
LZLianmin Zhang
Lianmin Zhang
Immune checkpoint blockade (ICB) has transformed cancer therapy, but its effect is often limited by immunosuppression and resistance mechanisms within the tumor microenvironment (TME). Cancer‐associated fibroblasts (CAFs) represent a major stromal component of the TME. They exhibit substantial heterogeneity, dynamic plasticity, diverse cellular origins, and context‐dependent activation states, which critically determine the safety and efficacy of CAF‐targeted therapies. CAFs contribute to tumor immune evasion by remodeling the extracellular matrix, altering tissue mechanics and establishing structural barriers. In addition, CAFs release cytokines, chemokines, and exosomes to impair T‐cell trafficking and function. They also interact with immune and myeloid cells, further reducing the efficacy of ICB. Therefore, CAF‐targeted therapies are shifting from the strategy of extensive clearance to a more elaborate framework, which focuses on specific CAF subpopulations and their regulatory pathways, and combines specific strategies for subpopulations, functional reprogramming, and methods based on advanced delivery systems and diagnostic tools. Integrating spatial omics, single‐cell technologies, and 3D culture systems can help us better understand the different states of CAFs and how they are distributed in space. This enables the identification of targetable CAF states, informs reprogramming strategies, supports rational combination design, and facilitates biomarker discovery. This review emphasizes the heterogeneity and plasticity of CAFs in tumor immunosuppression, and advocates a conceptual shift from static cellular identity to a dynamic state–niche–function framework.